Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.

Area of Science:

• Critical Care Medicine
• Regenerative Medicine
• Pulmonology

Background:

• The COVID-19 pandemic presented a critical need for effective treatments for severe acute respiratory distress syndrome (ARDS) in 2020.
• No definitive therapies existed for SARS-CoV-2, particularly for patients with severe COVID-19 ARDS.
• Mesenchymal stromal cells (MSCs) were investigated as a potential therapeutic option.

Purpose of the Study:

• To evaluate the efficacy of mesenchymal stromal cell (MSC) infusion in improving pulmonary function and patient outcomes.
• To assess the safety and tolerability of MSC therapy in critically ill COVID-19 ARDS patients.
• To determine if MSC treatment could enhance recovery in patients with severe respiratory compromise.

Main Methods:

• A cohort of critically ill COVID-19 ARDS patients with a Horovitz index <100 received MSC infusions.
• Five patients were treated with 1 million MSCs/kg body weight, administered intravenously over 30 minutes.
• Treatment was repeated up to three times in some patients; outcomes were compared to a control group.

Main Results:

• MSC infusion was found to be safe and well-tolerated in all treated patients.
• Patients receiving MSCs showed significantly improved Horovitz and reduced Murray scores upon discharge compared to controls.
• Survival to discharge was higher in the MSC group (80%) compared to the control group (45%), with improved pulmonary function observed.

Conclusions:

• Mesenchymal stromal cell (MSC) infusion represents a safe therapeutic approach for managing COVID-19 ARDS.
• MSC treatment significantly enhances pulmonary function and improves the overall clinical outcome for patients with severe COVID-19 ARDS.
• The study supports MSC infusion as a viable strategy to improve survival rates and lung recovery in this vulnerable patient population.